LATEST NEWS

April, 2013

Quarterly Activities Report - 31 March 2013

iSonea CEO to Present at Investor Forum

New Issue of iSonea Newsletter Available

New Investor Presentation

New issue announcement, application for quotation of additional securities and agreement

Change of Director’s Interest Notice

iSonea Launches New Asthmasense™ Cloud Technology

March, 2013

iSonea to Unveil New Asthma Technology at Australian Asthma Conference

iSonea Unveils Regulatory Plans for AirSonea™ Wheeze Monitor

February, 2013

iSonea Half Year Report

Dr. Stewart Washer Presentation to BioMelbourne Mobile Health Conference

Change of Director’s Interest Notice

January, 2013

iSonea Chairman to Present at BioMelbourne Mobile Health Conference

iSonea Q2 Report 2013

iSonea Announces Free Issuance Period for Conversion of KMLXF Shares to ISOAY ADRs

December, 2012

iSonea Previews AsthmaSense v1.1 at mHealth Summit

November, 2012

Results of Annual General Meeting

Change of Director’s Interest Notice: Washer

Change of Director’s Interest Notice: Dantzker

Change of Director’s Interest Notice: Korten

Change of Director’s Interest Notice: Haghighat

Change of Director’s Interest Notice: MacDonald

 

 

 

 

 

Technology

Acoustic Asthma Management

The iSonea technology is based on acoustic signal acquisition and processing, and advanced signal processing techniques. Acoustic markers such as wheezes, rhonchi and cough are recorded using propriety lung-sound sensors. These sensors are specifically designed for lung-sound detection and thus are more oriented in detecting sounds characteristic to asthma than normal stethoscopes.

The acquired data is analyzed by iSonea patented algorithms and signal-processing techniques, by mapping out the data’s spectral content in a graphical fashion. The software searches for spectral patterns specific to certain lung sounds, such as wheezes, rhonchi and cough, and marks their presence and duration on the graphical sonogram. Outside noises are cancelled out using patented ambient noise rejection techniques, to ensure the accuracy of physiological sound detection. The user can view a sonogram of the recording and listen to the amplified lung sounds to get a better grasp of the data.

Broncial Provocation Test Display

The criteria for detecting lung sound patterns conform to the guidelines set forth by CORSA (COmputeRized Sound Analysis), the multi-national collaboration that defined and standardized the lung sound terminology. This assures that the detection and quantification results of the PulmoTrack are universally accepted as true lung sound detections.

 

© 2013 iSonea (formerly Karmelsonix) Ltd| Disclaimer, Terms and Conditions, Copyright and Intellectual Property.

BlackFin Processor
BlackFin® Processor
KarmelSonix ISO Certification
iSonea
ISO Certification 2003
US Food & Drug Administration

US Food & Drug Administration
Australian Government

Australian Government
Therapeutic Goods Administration


CE Certification

CE Certification